NeurologyLive® Friday 5 — May 17, 2024

News
Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 17, 2024.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Building the Archetype for MOGAD Care: Introducing Mayo’s New Clinic

Mayo's MOGAD Clinic represents a new type of novel, multidisciplinary care, incorporating multiple different backgrounds of neurology, neuroimmunology, neuro—ophthalmology, and urology, among others.

Building the Archetype for MOGAD Care: Introducing Mayo’s New Clinic

2: Overlooked Neurological Features Present in Long COVID: Svetlana Blitshteyn, MD, FAAN

Svetlana Blitshteyn, MD, FAAN, the director of Dysautonomia Clinic talked about advocating for recognition and research into neurological symptoms that have long been overlooked in patients with Long COVID. [WATCH TIME: 3 minutes]

Overlooked Neurological Features Present in Long COVID: Svetlana Blitshteyn, MD, FAAN

3: CMSC 2024: What to Expect From This Year's Annual Meeting

The Consortium of Multiple Sclerosis Centers' 38th Annual Meeting will be held Wednesday, May 29, through Saturday, June 1, 2024 at the Music City Center, in Nashville, Tennessee. To find out more about the meeting, CMSC's own Tina Trott, and past president Scott D. Newsome, DO, shared their insight into the meeting that's coming up in just a few weeks.

CMSC 2024: What to Expect From This Year's Annual Meeting

4: NeuroVoices: Jessica Ailani, MD, on Implications of DELIVER Analysis With Eptinezumab for Migraine Prevention

In this week's NeuroVocies Q&A, Jessica Ailani, MD, the director of the MedStar Georgetown Headache Center, talked about results from an analysis on the DELIVER study assessing response rates of eptinezumab in patients with migraine over an 18-month period.

NeuroVoices: Jessica Ailani, MD, on Implications of DELIVER Analysis With Eptinezumab for Migraine Prevention

5: Open-Label Data vs Real-World Data for Anti-CD20 Therapies in Multiple Sclerosis

In episode 16 of the Peer Exchange video series titled "Anti-CD20 Monoclonal Antibodies and Future Directions in Multiple Sclerosis Care", Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss the utility of real-world data, particularly when it comes to understanding subtle differences between agents from both a safety and efficacy perspective.

Open-Label Data vs Real-World Data for Anti-CD20 Therapies in Multiple Sclerosis
Related Videos
R. Scott Turner, PhD, MD, FANA, FAAN
Video 5 - 5 KOLs are featured in "Managing Clinical Stability in Adults Spinal Muscular Atrophy Patients"
Video 5 - 5 KOLs are featured in "Key Players in Transitioning Patients with SMA from Pediatric Care to Adult Health Care"
Charbel Moussa, MBBS, PhD
Kelly Papesh, DNP, APRN, FNP-BC
Anvi Gadani, MD
David Shprecher, DO, MSci, FAAN
Jessica Ailani, MD
© 2024 MJH Life Sciences

All rights reserved.